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ABSTRACT 
Healthy rats had been treated for 2 or 6 weeks with 1.0 mL of and 10-l6 mg/ 
mL of cisplatin. After 2 weeks of treatment, a significant increase in leukocyte and 
erythrocyte count and also in hematocrit was observed. Among leukocytes the 
number of neutrophils and eosinophils significantly increased. Biochemical analy- 
ses indicated a decrease in the glycogen content in the liver and kidneys after 
2 weeks of treatment with low doses of cisplatin but at the end of the experiment 
(8th week of experiment) the stores of glycogen increased significantly. Biochemi- 
cal analyses concerning the activity of some enzymes in the liver revealed a signifi- 
cant increase of peroxidase and acid phosphatase as well as catalase activities after 
2 weeks of treatment. However, catalase was induced by a very low concentration of 
cisplatin, 10-l6 mg/mL. After the cessation of cisplatin treatment the activity of 
enzymes returned to normal values. 
Human lung carcinoma cell line A,,, (ECACC No 86012804) was also studied 
after treatment with the same doses of cisplatin and inhibition of its growth was 
observed. The results of these experiments strongly indicated that low doses of 
cisplatin could be stimulating for healthy cells but cytostatic for tumor cells. 
Possible mechanisms involved in the biological activity of very low cisplatin 
concentrations are discussed. 
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INTRODUCTION 
Cisplatin is an antineoplastic agent that is used commonly in human and veteri- 
nary medicine to treat a variety of malignant tumors of testicles, prostate, ovaries, 
and lungs. Cisplatin is one of the most active agents in lung cancer with a high 
response rate in small cell lung carcinoma (Arbaye et al. 1993; Ogilvie et al. 1992). 
In the doses used for anti-tumor therapy, cisplatin is a very toxic substance that 
induces nephrotoxicosis, bone marrow injury with anemia, trombocytopenia, and 
other adverse effects such as blindness, deafness, severe nausea, vomiting, hearing 
loss, and allergic reactions. 
Because of such high toxicity of cisplatin, it was interesting to examine whether 
low doses of this cytostatic drug could inhibit tumor cell growth in vitro and whether 
a long-term treatment of healthy animals with very low cisplatin concentrations 
could exert a toxic effect. According to hormesis, we expected a decrease in 
organism intoxication as well as an increase in its vitality under the influence of very 
low doses of the same substance, which is known to exert toxic effects. 
Wagner et al. (1988) examined the influence of the broad concentration range 
of cytotoxic and such cytostatic agents as emetin, plumbagin, azatioprine, colchi- 
cine, cyclophosphamide, fluorouracil, methotrexate, and vinblastine on human 
granulocytes and lymphocytes in vitro. Most of the examined compounds showed a 
dosedependent biphasic effect: immunosuppressive activity at a concentration higher 
than 100 ng/mL and immunostimulatory activity at a very low concentration below 
100 pg/mL. 
Hormesis together with the inverse effect of high and low doses of toxic sub- 
stances can explain this phenomenon. There are several papers in the literature 
concerning this problem (Calabrese 2001; Calabrese and Baldwin 2001). Wagner et 
al. (1988) showed that cytostatic agents inhibit the growth of lymphocytes at concen- 
trations ranging from 100 mg/mL to 10 pg/mL, but stimulate the growth at 
picogram and ferntogram concentrations. A similar dose-dependent effect on phago- 
cytic activity of human granulocytes was observed with emetin and plumbagin, 
which were toxic at high concentrations, but at very low concentrations they stimu- 
lated the phagocytosis of granulocytes. According to the paper by Davenas et al. 
(1987), silica particles, which are very toxic for phagocytes, can stimulate macroph- 
age function measured by increased amounts of platelet activating factor (PAF) 
released when mice were injected with very low silica doses (1000 silica particles or 
less per mouse). 
The blood cells are constantly renewed during an individual's lifetime. He- 
mopoiesis is a very complex process, which is regulated at different levels and by 
various factors. The most important factors for the regulation of hemopoiesis were 
recognized as IL-3, CSF-1, GCSF, GM-CSF, and erythropoietin. They are involved in 
growth regulation and the differentiation of blood cell precursors (Bastide et al. 
1987). 
The aim of this paper is to collect and compare physiological data of healthy 
animals and tumor cell cultures treated with very low doses of cisplatin. Proper levels 
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of enzymes in the liver and proper hematological parameters are very important 
markers of good health. For this reason the main hematologic parameters were 
determined in the blood of rats, which had been treated per os with low doses of 
cisplatin. At the same time, the activities of catalase, peroxidase, as well as alkaline 
and acid phospahatases were determined in livers because of their physiological 
function in organism detoxication. The results of these experiments were compared 
with the reaction of tumor cells growing in vitro and treated with identical dilutions 
of cisplatin as those used in animal analyses. 
MATERIALS AND METHODS 
Preparation of Cisplatin Dilutions 
One mg of cisplatin (Ciba Geigy) was dissolved in 1 ml of double distilled water 
and 100-fold dilutions from to 10-l6 mg/mL were prepared serially and were 
vigorously mixed after each stage. The dilutions lo-* (as a concentration of cisplatin 
that can be detected by sensitive methods) and 10-l%g/mL (as a concentration 
approaching Avogadro's number) were chosen and used in all experiments. 
Treatment of Tumor Cells 
Human lung carcinoma cell line %, (European Collection ECACC No 86012804) 
was grown at 37°C in an atmosphere containing 5% CO, in Eagle's MEM supple- 
mented with 10% fetal calf serum and antibiotics (100 U/mL penicillin and 100 pg/ 
mL streptomycin). All the experiments were carried out on cells that after trypsiniza- 
tion were seeded at the density of 1 x lo5 cells/mL on plastic Petri dishes (82 mm 
in diameter). After the adhesion of the cells, the medium was removed and 0.9 mL 
of fresh medium and 0.1 mL of cisplatin dilution were added to the respective 
dishes. Cell controls were treated with 0.1 mL of distilled water instead of cisplatin. 
Four plastic plates were used for each dilution and control. The experiments were 
repeated three times. Cell cultures were incubated at 37OC for 72 h. The culture 
medium was discarded, the cells were rinsed in phosphate-buffered saline (PBS), 
and 1 mL of 0.025% solution of trypsin in PBS was added. The cells suspended in 
trypsin solution were counted under the microscope in a hemocytometer and cell 
viability was determined by standard trypan blue exclusion test (Szalewicz et al. 
1992). The protein level in the cells was determined with the Lowry et al. (1951) 
method after washing the cells in PBS. Absorbance at 660 nm was measured by 
spectrophotometry (Shimazu Gmbh, Japan W-1202). 
Animal Treatment 
Forty-eight 5-week-old Lewis rats were divided into three groups, 8 male and 8 
female in each group. They were fed on a standard laboratory solid diet supple- 
mented with raw potatoes and carrots as a source of vitamin C and A. During the 
experiment, every morning at 8 a.m., each animal received peros one mL of cisplatin 
dilution, either (10 picograms/mL) or 10-l6 (10 nttograms/mL) mg/mL, instead 
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of drinking water. After that they had a free access to water only during the day but 
not during the night. Control rats received an equivalent volume of distilled water. 
Drinking water was provided in new glass bottles with rubber stoppers and glass 
tubing. Food consumption, behavior, skin lesions, diarrhea, and other external 
abnormalities were recorded every day. During the 2 weeks of treatment with 
dilution 10-8rng/mL of cisplatin, each rat received a total of 140 picograms of the 
drug. Rats treated with dilution 10-l6 mg/mL received a total of 140 attograms of 
cisplatin per animal. After 6 weeks of treatment rats received, respectively, 420 
picograms or 420 attograms per animal. After 6 weeks of treatment with cisplatin 
hematological and enzymatic parameters of 16 rats were also estimated 2 weeks after 
cessation of drug treatment (8th week of experiment). During those additional 2 
weeks rats had a free access to water and food. 
Hematological Variables 
In the second week and the sixth week, as well as 2 weeks after the sixth week of 
treatment (8th week of the experiment) the blood samples were collected under 
deep ether anesthesia. Before blood collection, the animals had a free access to 
drinking water for 24 h to prevent dehydratation. Differential blood counts were 
performed using routine methods. The numbers of red and white cells were counted 
in a hernocytometer. Hernatocrit was established in a hernatocrit centrifuge and 
hemoglobin content was measured by routine cyanornethemoglobin method. Dif- 
ferential blood counts were performed on Giemsa stained blood smears by counting 
the minimum of 200 white blood cells per each smear. 
Biochemical Determinations 
Livers were taken from rats after blood sampling, washed in phosphate-buffered 
saline, and homogenized in a glass homogenizer in cold buffer and centrifuged. 
Enzyme activities were determined in the supernatant. Also, kidneys were taken 
from rats after the last blood sampling, washed in phosphate-buffered saline, ho- 
mogenized in a glass homogenizer in cold buffer, centrifuged, and the level of 
glycogen was measured. 
Catalase activity was measured according to the Hamilton et al. (1961) method. 
Two mL of the supernatant were mixed with 7 mL of distilled water and 2 mL of 1 % 
H20,. The rate of H202 degradation was measured at 240 nm. One unit of the 
activity was considered as the amount of the enzyme, which degraded one rng of 
H202. 
Peroxidase activity was measured in accordance with Clairborne and Fridovich 
(1979), the method based on odianisidine oxidation in the presence of 0.003% 
H202in 0.1 M acetic buffer, pH 5.5. The relative activity was calculated on the basis 
of the absorbance coefficient = 11.3. 
Alkaline and acid phosphatase activities were calculated on the basis of the rate 
p-nitrophenol release from 2.5 mM nitrophenyl phosphate at pH 5 or pH 8.6, 
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respectively, according to Szalewicz et al. (1992). The hydrolysis of one pM of the 
substrate per minute was considered as the activity unit. 
The level of glycogen in livers and in kidneys of the tested animals was measured 
according to the Babcock and Cardell method (1974) and calculated in pg per mg 
of tissue dry weight. 
The Student's t test was used for statistical analysis of the results. 
RESULTS 
CeU Cultures 
As shown in Figure 1, cisplatin tested at concentrations of 1 pg/mL inhibited the 
growth of &, cells, when compared with control cultures treated with water. Cell 
numbers and protein levels were lower in the cultures treated with cisplatin, com- 
pared with control cultures treated with water. Compared with control where few 
dead cells were present and the viability of cells was 99%, the number of viable cells 
after a treatment with cisplatin concentration of 1 pg/mL decreased to 78%. 
Moreover, low concentrations of cisplatin equal to 10 fig and 0.1 ag/mL were also 
active and inhibited cell growth. Especially the concentration of cisplatin 0.1 ag/mL 
significantly decreased cell numbers and protein concentration. This dilution of 
control f ug/ml 10 pg/ml 0,l ag/ml 
Cisplatin concentratiot 
Figure 1. The number (mean B D )  of tumor cells line k,, and the level of cell protein 
(OD660 x lo2) after the treatment with pica- and attograms/mL of cisplatin (* 
statistically significant difference at pc0.05 compared with control). Error bars 
indicate standard deviation (SD). 
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cisplatin was cytostatic rather than cytotoxic, because the viability of cells in cultures 
was between 95% and 97%. 
Observations of Animals Treated with Cisplatin 
All tested animals were observed during the treatment with low cisplatin doses. 
No significant statistical differences were observed between control and experimen- 
tal animals concerning food consumption and behavior; no weight loss, skin lesions, 
diarrhea or other specific abnormalities were noticed. 
Hematological Measurements 
The influence of low doses of cisplatin on some hematological parameters in rats 
was examined. Two dilutions of cisplatin were chosen for experiments: mg/mL 
and 10-l6 mg/mL. Rats treated with both dilutions of cisplatin had increased total 
erythrocyte and leukocyte count, and a higher hematocrit and hemoglobin concen- 
tration (Table 1). The differences were especially visible and statistically significant 
in comparison with control after treating rats with picogram doses. After 6 week of 
treatments this dilution was still more active than the attogram doses; however, the 
differences in comparison with control were not statistically significant. Differential 
leukocyte counts revealed increased numbers of neutrophils and eosinophils in the 
blood (Table 2). It should be stressed that all hematological parameters were still 
within the range considered as normal in rats. These parameters were also evaluated 
2 weeks after the cessation of drug treatment. As shown in Table 1 and Table 2, they 
returned to normal and no statistically significant differences between control and 
experimental animals could be observed. Blood cell counts, hematocrit index, and 
the number of neutrophils and eosinophils returned to the values observed in 
control animals. 
Enzymatic Activity Detection 
The level of activity of four enzymes: catalase, peroxidase, and two phosphatases 
were measured in the liver homogenates after 2 and 8 weeks of treatment of rats with 
low doses of cisplatin. Figure 2 shows the results of enzymatic experiments. The 
patterns of every enzyme activity were different. When rats were treated with pico 
concentrations of cisplatin, peroxidase and acid phosphatase were significantly 
higher than in control, but they decreased after 8 weeks (6-week treatment + 2 weeks 
of interval). Compared with the enzymes mentioned above, alkaline phosphatase 
activity was higher at the end of the experiment rather than at the beginning. After 
2 weeks of treatment, the activity of catalase was stimulated with a low concentration 
of cisplatin (10-l6 mg/mL). It is worth mentioning that the levels of acid and alkaline 
phosphatases, catalase, and peroxidase at the end of the experiment, 2 weeks after 
cisplatin cessation, were more similar to controls than at the beginning. However, 
they never fell below the level observed in control. 
Figure 3 shows the glycogen levels in the liver and kidneys during and after 
cisplatin treatment of rats. The differences in the levels of glycogen during and after 
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3 
5' weeks (2 weeks after 6 weeks of cisplatin treatment) ('statistically significant difference in comparison 
0 to control at pc0.05). The results are presented as a mean k SD. 3. 
*- 140 picograms, **- 14 0 attograms; 
* - statistically significant difference at p< 0.05 in comparison to control. 
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Table 2. The influence of cisplatin treatment on differential leukocyte count in rats after 2, 6, 
and 8 weeks (2 weeks after the 6-week treatment) of pice and attegrams/ml of 
cisplatin (* statistically significant difference at p c 0.05 in comparison to control). 
The results are presented a s  a mean f SD. 
I Duration of I Cisplatin dilution 1 Differential leukocyte counts (%) I 




n =  16 







* - 14 Opicograms; ** - 140 atlograms; N - neutrophils, L lymphocytes, E eosinophils, M - monocytes, B - basophils; 
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w lo(-8) lo(-1 6)  C 
Cisplatin dilution 
1 0(-8) 1 O(-16) 
Cisplatin dilution 
Figure 3. The level of glycogen in rat livers and kidneys after 2 and 8 weeks (2 weeks after 
6week treatment) of pico- and attegrams/mL of cisplatin (* statistically signifi- 
cant difference at p < 0.05 compared with control). Error bars indicate standard 
deviation (SD). 
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experiments with cisplatin exceeded no more than 10 pg in kidneys. In the liver, the 
level of glycogen was lower than control after 2 weeks of treatment and higher after 
finishing cisplatin administration. 
DISCUSSION 
It has been shown that cisplatin induces oxidative stress in the organism by 
generating oxygen free radicals in macrophages, platelets, and kidney cells and by 
inhibiting antioxidant enzyme activity, such as peroxidase and superoxide dismutase 
(Son and Kim 1995; Sugihara et al. 1987; Wachowicz and Szwarocka 1994; Wachowicz 
et al. 1995). It is well known that antioxidant enzymes play a fundamental role in 
protecting cells and tissues against oxidative damage (Andersen et al. 1997; Scandalios 
1992; Batzer and Agganval 1986; Bishayi et al. 2002). The activity of these enzymes 
increases in the organism when reactive oxygen species are generated. As high 
concentrations of cisplatin can inhibit at least some of the antioxidant enzyme 
activity, it was important to examine if low concentrations of cisplatin can influence 
such activity. Two so-called "stress enzymes", catalase and peroxidase, were chosen 
for experiments. 
Mammalian catalase is abundant in the liver, where the enzyme resides mainly in 
peroxisomes and plays an important role in eliminating H,O, generated during the 
dismutation of superoxide anion by SOD. Peroxidase works in a similar way, how- 
ever, it acts when the amount of hydrogen peroxide is low. In our experiments 
picogram doses of cisplatin inhibited catalase activity in rat liver. However, lower 
attogram doses of cisplatin significantly stimulated its activity, especially after 2 weeks 
of treatment. When peroxidase activity was measured by oxidation of aromatic 
compounds such as o-dianisidine, a significant increase in its activity was detected in 
the liver of the rats which received the picogram doses of cisplatin. The attogram 
doses of cisplatin were not active. These observations suggest that cisplatin at very 
low doses can stimulate the activity of the antioxidant enzyme system in the liver. 
This phenomenon can be explained by the reverse activity of the high dose, which 
can inhibit the activity of cells and enzymes, and of the low dose, which stimulates 
it. 
Hepatotoxicity is not considered as a dose-limiting toxicity for cisplatin, but liver 
toxicity can occur when the antineoplastic drug is administered at a high dose 
(Charalabopoulos et al. 2002; Cersosimo 1993; Bishayi et al. 2002; Zicca et al. 2002; 
Ueda et al. 1998). Alkaline phosphatase and especially its isoform present in the liver 
(LALP) are very often used as markers of hepatic subacute toxicity of antineoplastic 
agents (Pispirigos et al. 1993). It has been detected that ciplatin inhibits strongly 
LALP in the liver of dogs suffering from appendicular osteosarcoma (Garzotto et al. 
2000) and also alkaline phosphatase and acid phosphatase in rat kidneys (Fenoglio 
et al. 2002). Therefore, we decided to measure the activity of two phosphatases, 
alkaline and acid isoforms, present in the liver. A significant increase in peroxidase 
activity was also accompanied by a significant increase in the activity of acid phos- 
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phatase. It should be pointed out that in our experiments the activity of alkaline 
phosphatase, which increases in the liver during infections and can also be induced 
by stress, was rather inhibited by low-dose cisplatin treatment and returned to 
normal level after cessation of drug treatment. It seems likely that different enzymes 
may be regulated differently by low doses of cisplatin. 
According to the opposite activity of high and low doses of certain biologically 
active substances, we expected that cisplatin, an anticancer drug, would stimulate 
tumor cell growth in vitro. To our surprise, cisplatin at attogram concentrations 
inhibited tumor cell growth in vitro in comparison with untreated control. The 
activity of low cisplatin concentration was not as strong as cisplatin used at micro- 
gram concentrations; however, the effect measured by two different methods was 
detectable. 
There arose a question whether the changes observed in the hematologcal 
parameters in the blood of experimental animals were the consequence of a direct 
action of cisplatin on progenitor cells in bone marrow or whether cisplatin is able 
to influence the production and action of several growth factors. The toxicity of 
cisplatin, at therapeutic doses, to bone marrow cells is evident and probably cisplatin 
can trigger apoptosis and affect cell cycle causing anemia and a decrease in leuko- 
cyte count. These effects are reversible after drug discontinuation (Holdack el al. 
1992; Mazur et al. 2002; Sachs and Lotem 1994). In our experiments cisplatin at low 
doses acted as mild stimulator of bone marrow function that resulted in an increase 
of the total number of leukocytes and erythrocytes. Differential leukocyte counts 
revealed that this increase was caused mainly by an increase in the number of 
neutrophils and eosinophils. The results of our experiments on rats are in agree- 
ment with the observations of Wagner et al. (1988), Holldack et al. (1992) and Sodhi 
and Pai (1992). They indicated that very low doses of cisplatin could stimulate bone 
marrow to produce red cells with higher hemoglobin content and high numbers of 
white blood cells. 
The blood cells are constantly renewed during an individual's lifetime. He- 
mopoiesis is a very complex process that is regulated at different levels and by 
different factors, such as IL-3, M-CSF, GCSF, GM-CSF, erythropoietin. These cytokines 
are involved in growth regulation and the differentiation of blood cell precursors 
(Sodhi and Pai 1992; Holldack et al. 1992). We can only speculate that low doses of 
cisplatin can influence cell cycles or cytokine production and in the final effect 
stimulate bone marrow activity. 
It has been detected recently that, depending on the concentration, cytokines 
may exert opposite effects. For example, M-CSF at a high (5 U/mL) concentration 
activates the extracellular signal-regulated kinase (ERK) pathway, while a low (0.05 
U/mL) concentration reduces ERK phosphorylation and affects cell proliferation 
(Rovida el  al. 2002). Moreover, tumor necrosis factor (TNF) at a low concentration 
(1 U/mL) decreases myofibrillar protein content, while at relatively high concentra- 
tions (100 U/mL or more) increases protein content in muscle cell line (Alvares et 
al. 2001). Cisplatin, at high concentrations, possesses clastogenic activity in bone 
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marrow; however, by modulation of cytokine production it may exert an opposite 
effect on bone marrow cells. It is worth mentioning that aflatoxin B, a natural 
cytotoxic substance, also exerts opposite effects: at high doses (280 ppb) stimulates 
bone marrow, while at a low dose (140 ppb) decreases total number of white blood 
cells in piglets (Marin et al. 2002). 
All these results strongly indicate that low doses of toxic substances such as 
cisplatin could stimulate healthy cells but inhibit tumor cell growth. It is possible 
that these opposite reactions of animal cells to toxins used at low or high concen- 
trations are the result of differential influence on the apoptotic mechanism in 
normal and pathological cells (Calabrese 2001). 
The protective effect of high dilutions of metal on cultured cells was demon- 
strated by Delbancut et al. (1997). Cisplatin was used at  a cytotoxic concentration 
M), but protective doses of cisplatin or  cadmium were used at high dilutions 
(10-lo and higher). The protective index of cadmium against cisplatin cytotoxicity 
was weak, but it was more pronounced for the cells pretreated with low doses of 
cisplatin. It means that 10" M cisplatin killed only 63% of cisplatin-pretreated cells, 
while it killed 68.4% of cadmium-pretreated cells. These experiments confirmed the 
rule that the effectiveness of the pretreatment requires the use of the same sub- 
stance for protecting cells against the toxic effect (Van Wijk and Wiegant 1997). 
The results of the experiments, showing that very low doses of cisplatin are not 
dangerous to animal health but are toxic to tumor cells, opened the possibility of 
using low doses for protecting patients against adverse effects of anticancer therapy. 
REFERENCES 
Alvarez B, Quinn LS, Busquets S, Lopez-Soriano FJ, and Argiles JM. 2001. Direct effects of 
tumor necrosis factor alpha on murine skeletal muscle cell lines. Bimodal effects on 
protein metabolism. Eur Cytokine Netw 12:399410 
Andersen HR, Nielsen JB, Nielsen F, and Grandjean P. 1997. Antioxidative enzyme activities 
in human erythrocytes. Clin Chem 43:562-568 
Arbaye YM, Bittner G, Yingling JM, Storer B, and Schiller JH. 1993. Antiproliferative effects 
of interferon -and - in combination with 5-fluorouracil, cisplatin and cis and trans-retinoic 
acid in the three human lung carcinoma cell lines. J Interferon Res 13:25-32 
Babcock MB and Cardell RR. 1974. Hepatic glycogen patterns in fasted and fed rats. Am J 
Anat 140:299-338 
Bastide M, Daurat V, Doucet-Jaboeuf M, Pelergin A, and Dorfman P. 1987. Immunomodulator 
activity of very low doses of thymulin in mice. Int J Immunol 3:191-200 
Batzer MA and Aggarwal SK. 1986. An in vitro screening system for the nephrotoxicity of 
various platinum coordination complex. Cancer Chemother Pharmacol 17209-217 
Rishayi B, Roychowdhury S, Ghosh S, and Sengupta M. 2002. Hepatoprotective and 
imn~unomodulatory properties of Tinospora cordifolia in CC14 intoxicated mature albino 
rats. J Toxicol Sci 27:139-146 
Calabrese EJ. 2001. Apoptosis:Biphasic dose responses. Critical Rev Toxicol 31:607-15 
Calabrese EJ and Baldwin LA. 2001. Hormesis: A generalizable and unifying hypothesis. 
Critical Rev Toxicol 31:353424 
Nonlinearity in Biology, Toxicology, and Medicine. Vol. 1, No. 1, 2003 135 
13
Malarczyk et al.: The Influence of Very Low Doses of Cisplatin on Tumor Cells
Published by ScholarWorks@UMass Amherst, 2007
Malarczyk et al. 
Cersosimo RJ. 1993. Hepatotoxicity associated with cisplatin chemotherapy. Ann Pharmacother 
27:438441 
Charalabopoulos K, Karkabounas S, Ioachim E, Papalimneou V, Syrigos K, Evangelou A, 
Agnantis N, and Hadjiliadis N. 2002. Antitumour and toxic effects on Wistar rats of two 
new platinum complexes. Europ J Clin Invest 32:129-133 
Claiborne A and Fridovich J. 1979. Chemical and enzymatic intermediates in the peroxidation 
of o-dianisidine by horseradisch peroxidase. Biochemistry 18:23242329 
Davenas E, Poitevin B, and Beneviste J 1987. Effect on mouse peritoneal macrophages of 
arally administered very high dilution of silica. Eur J Pharmacol 135:313-319 
Delbancut A, Barouillet MP, and Cambar J. 1997. Evidence and mechanistic approach of the 
protective effects of heavy metal high dilutions in rodents and renal cell cultures. In: 
Bastide M (ed), Signals and Images, pp 71-82. Kluwer Acad. Publ., Netherlands 
Fenoglio C, Boicelli CA, Ottone M, Addario C, Chiari P, and Viale M. 2002. Protective effects 
of procaine hydrochloride on cisplatin-induced alterations in rat kidneys. Anticancer 
Drugs 13: 1043-1054 
Garzotto CK, Berg J, Hoffmann WE, and Rand WM. 2000. Prognostic significance of serum 
alkaline phosphatase activity in canine appendicular osteosarcoma. J Vet Intern Med 
14:587-592 
Hamilton HB, Nishimura ET, Kobara TY, Takahara S, and Maddon SC. 1961. Immunologic 
evidence of catalase deficiens in human hereditary acatalasemia. Lab Invest 10:3340 
Holldack J, Burdach S, Eisberg A, Frisch J, and Schultz G. 1992. Biology and pharmacology 
of hematopoietic growth factors. Med Pediatr Oncol 2:2-9 
Lowry J, Resenbrough NJ, Farr AL, and Randall PJ. 1951. Protein measurement with Folin 
phenol reagent. J Biol Chem 193:265-275 
Marin DE, Taranu I, Bunaciu RP, Pascale F, Tudor DS, Avram N, Sarca M, Cureu I, Criste RD, 
Suta V, and Oswald IP. 2002. Changes in performance, blood parameters, humoral and 
cellular immune responses in weanling piglets exposed to low doses of aflatoxin. J Anim 
Sci 80:1250-1257 
Mazur L, Czyzewska A, and Bochenek M. 2002. Flow cytometric detection of apoptotic bone 
marrow cells with fractional DNA content after application of WR-2721, cyclophospha- 
mide, cisplatin, and exposure of mice to gamma rays. Hum Exp Toxicol 21:335-341 
Ogilvie GK, Fettlnan MJ, Jameson VJ, Walters LM, Lafferty MH, Cooper MF, Powers BE, 
Ciekot PA, Atwater SW, and Withrow SJ. 1992. Evaluation of a one-hour saline diuresis 
protocol for administration of cisplatin to dogs. Am J Vet Res 53:1666-1669 
Pispirigos K, Catsoulakos P, and Karakiulakis G. 1993. Evaluation of kidney and liver subacute 
toxicity of antitumor agents using serum biochemical parameters in rats. Biochem Mol 
Biol Int. 31:565-573 
Rovida E, Baccarini M, Olivotto M, and Sbarba PD. 2002. Opposite effects of different doses 
of M-CSF on ERK phosphorylation and cell proliferation in macrophages. Oncogene 
23:3670-3676 
Sachs L and Lotem J. 1994. The network of hematopoietic cytokines. Proc Soc Exp Biol Med 
206: 170-1 75 
Scandalios JG. 1992. Molecular biology of free radical scavening system. Scandalios JG (ed), 
pp 117-152, Cold Spring Harbor Laboratory Press 
Sodhi A and Pai K. 1992. Increased production of interleukin-1 and tumor necrosis factor by 
human monocytes treated in vitro with cisplatin or other biological response modifiers. 
Immunol Lett 34183-188 
136 Nonlinearity in Biology, Toxicology, and Medicine. Vol. 1, No. 1, 2003 
14
Dose-Response: An International Journal, Vol. 1 [2007], Iss. 1, Art. 7
https://scholarworks.umass.edu/dose_response/vol1/iss1/7
Influence of Cisplatin on Tumor Cell and Animal Health Conditions 
Son K and KimYM. 1995. In vivo cisplatin-exposed macrophages increase immunostimulant- 
induced nitric oxide synthesis for tumor cell killing. Cancer Res 55:55245527 
Sugihara K, Nakano S, and Gemba M. 1987. Effects of cisplatin on in vitro production of lipid 
peroxides in rat kidney cortex. J Pharmacol 44:71-76 
Szalewicz A, Janska H, Strzelczyk B, and Kubicz A. 1992. Amino acid composition and 
immunochemical properties of AcPase I11 and AcPase N representing glycoforms of the 
lower molecular weight tartrate-resistans acid phosphatase of the frog liver. Int J Biochem 
24:975-979 
Ueda H, Sugiyama K, Yokota M, Matsuno K, and Ezaki T. 1998. Reduction of cisplatin toxicity 
and lethality by sodium malate in mice. Biol Pharm Bull 21:34-43 
Van Wijk Rand Wiegant FAC. 1997. Stimulation of cellular self-recovery by application of the 
silmilia-principle. In: Bastide M (ed), Signals and Images, pp 53-61. Kluwer Acad. Publ., 
Netherlands 
Wachowicz B, Krajewski T, Olas B, and Zbikowska HM. 1995. Effects of cisplatin and selenite 
on the level of thiol in pig blood platelles. J Physiol Pharmacol 46:97-103 
Wachowicz B and Szwarocka A. 1994. Response of pig blood platelets to cisplatin and sodium 
selenite: Lipid peroxidation and oxygen radicals generation. Biomed Lett 49:147-152 
Wagner H, Kreher B, and Jurcic K. 1988. In vitro stimulation of human granulocytes and 
lymphocytes by pico and ferntogram quantities of cytostatic agents. Arzheim Forsch Drug 
Res 38:273-275 
Zicca A, Cafaggi S, Mariggio MA, Vannozzi MO, Ottone M, BocchiniV, Caviglioli G, andViale 
M. 2002. Reduction of cisplatin hepatotoxicity by procainamide hydrochloride in rats. 
Europ J Pharmacol442:265-272 
Nonlinearity in Biology, Toxicology, and Medicine. Vol. 1, No. 1, 2003 
15
Malarczyk et al.: The Influence of Very Low Doses of Cisplatin on Tumor Cells
Published by ScholarWorks@UMass Amherst, 2007
